news
Kisqali offers survival benefit for breast cancer patients, finds study
Analysis of HR+/HER2- patients treated in first-line with Kisqali plus fulvestrant demonstrated a significant OS benefit of nearly 16 months over fulvestrant alone.
List view / Grid view
ribociclib
news
Kisqali increases overall survival in advanced breast cancer patients by 12 months
Kisqali plus letrozole achieved a median overall survival (OS) of over five years (63.9 months), with OS benefit increasing over time, according to newly published data.
news
Ribociclib could be used to treat glioblastoma
Ribociclib, a drug approved to treat breast cancer, could be used to treat one of the deadliest forms of cancer - glioblastoma...
news
NICE recommends Kisqali as a cost-effective treatment for advanced breast cancer
NICE recommends Kisqali as a cost-effective treatment option for postmenopausal women within England and Wales with advanced breast cancer...
news
FDA approves Verzenio for metastatic breast cancer
The FDA has approved Verzenio to treat advanced or metastatic breast cancer that has progressed after taking therapy...
news
Novartis receives EU approval for ribociclib
Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer
